AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 11222890 — intervention group
Group type: EXPERIMENTAL
Intervention: Metal-backed tibial component
Number of subjects: 42
Study 11222890 — intervention group
Group type: COMPARATOR
Intervention: All-polyethylene tibial component
Number of subjects: 42
Study 9052344 — intervention group
Group type: EXPERIMENTAL
Intervention: Fast pathway (F-F)
Number of subjects: 17
Study 9052344 — intervention group
Group type: EXPERIMENTAL
Intervention: Slow pathway (S-S)
Number of subjects: 17
Study 8279842 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgical adjuvant chemotherapy for colorectal cancer; details on dosage and duration not available.
Number of subjects: 0
Study 8279842 — intervention group
Group type: COMPARATOR
Intervention: Not applicable; control group details not available.
Number of subjects: 0
Study 3548934 — intervention group
Group type: EXPERIMENTAL
Intervention: Geriatric consultation service
Number of subjects: 113
Study 3548934 — intervention group
Group type: COMPARATOR
Intervention: No geriatric consultation service (Control)
Number of subjects: 113
Study 29036016 — intervention group
Group type: EXPERIMENTAL
Intervention: Multimodal supervised aerobic, resistance, and flexibility exercises (EX; n = 28) for 3 months
Number of subjects: 57
Study 29036016 — intervention group
Group type: COMPARATOR
Intervention: Usual care (CON; n = 29) for 3 months
Number of subjects: 57
Study 27027416 — intervention group
Group type: EXPERIMENTAL
Intervention: Obese patients (BMI ≥30)
Number of subjects: 518
Study 24102976 — intervention group
Group type: EXPERIMENTAL
Intervention: Urologists performing IPG placement after stage I testing
Number of subjects: 0
Study 24102976 — intervention group
Group type: COMPARATOR
Intervention: Gynecologists performing IPG placement after stage I testing
Number of subjects: 0
Study 24102976 — intervention group
Group type: EXPERIMENTAL
Intervention: Gynecologists performing battery placement after percutaneous testing
Number of subjects: 0
Study 24102976 — intervention group
Group type: COMPARATOR
Intervention: Urologists performing battery placement after percutaneous testing
Number of subjects: 0
Study 24102976 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients treated by high-volume providers
Number of subjects: 0
Study 24102976 — intervention group
Group type: COMPARATOR
Intervention: Patients treated by low-volume providers
Number of subjects: 0
Study 24102976 — intervention group
Group type: EXPERIMENTAL
Intervention: Women undergoing SNM
Number of subjects: 0
Study 24102976 — intervention group
Group type: COMPARATOR
Intervention: Men undergoing SNM
Number of subjects: 0
Study 21982737 — intervention group
Group type: EXPERIMENTAL
Intervention: Extensive ultrasound protocols including measurement from the carotid bifurcation and internal carotid artery
Number of subjects: 94
Study 21982737 — intervention group
Group type: EXPERIMENTAL
Intervention: Reduced number of angles in ultrasound protocols
Number of subjects: 94
Study 21982737 — intervention group
Group type: EXPERIMENTAL
Intervention: Reduced number of sites in ultrasound protocols
Number of subjects: 94
Study 21982737 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher body mass index
Number of subjects: 94
Study 20079369 — intervention group
Group type: EXPERIMENTAL
Intervention: Worksite intervention program including enhancement of physical activity facilities, increased availability of and lower prices on healthy vending machine choices, and group behavioral programs.
Number of subjects: 0
Study 20079369 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified in detail).
Number of subjects: 0
Study 18270817 — intervention group
Group type: EXPERIMENTAL
Intervention: General anesthetic with propofol induction and maintenance
Number of subjects: 26
Study 18270817 — intervention group
Group type: COMPARATOR
Intervention: General anesthetic with thiopental induction and isoflurane maintenance
Number of subjects: 26
Study 15797167 — intervention group
Group type: EXPERIMENTAL
Intervention: RAVLT combined indices (true recognition + implicit memory score + automatic memory score)
Number of subjects: 61
Study 15797167 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard RAVLT administration (true recognition + primacy recognition)
Number of subjects: 61
Study 15797167 — intervention group
Group type: COMPARATOR
Intervention: Standard recognition score
Number of subjects: 61
Study 11817496 — intervention group
Group type: EXPERIMENTAL
Intervention: Lisuride for 6 months
Number of subjects: 120
Study 11817496 — intervention group
Group type: EXPERIMENTAL
Intervention: Anticraving drug expectancy
Number of subjects: 120
Study 11817496 — intervention group
Group type: EXPERIMENTAL
Intervention: Lisuride
Number of subjects: 120
Study 11817496 — intervention group
Group type: EXPERIMENTAL
Intervention: Dopaminergic responsivity to apomorphine stimulation
Number of subjects: 120
Study 11817496 — intervention group
Group type: COMPARATOR
Intervention: Placebo for 6 months
Number of subjects: 120
Study 10519493 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined spinal-epidural analgesia
Number of subjects: 100
Study 10519493 — intervention group
Group type: COMPARATOR
Intervention: Epidural analgesia
Number of subjects: 100
Study 7554698 — intervention group
Group type: EXPERIMENTAL
Intervention: Chloroguanide (200 mg orally)
Number of subjects: 20
Study 7554698 — intervention group
Group type: EXPERIMENTAL
Intervention: Chloroguanide with omeprazole (40 mg/day for 7 days)
Number of subjects: 20
Study 7554698 — intervention group
Group type: COMPARATOR
Intervention: Mephenytoin (100 mg orally)
Number of subjects: 20
Study 2202384 — intervention group
Group type: EXPERIMENTAL
Intervention: Zabicipril 2.5 mg
Number of subjects: 42
Study 2202384 — intervention group
Group type: EXPERIMENTAL
Intervention: Zabicipril (0.03 to 10 mg)
Number of subjects: 42
Study 2202384 — intervention group
Group type: EXPERIMENTAL
Intervention: Zabicipril
Number of subjects: 42
Study 7261552 — intervention group
Group type: EXPERIMENTAL
Intervention: Propranolol (80 mg b.i.d.)
Number of subjects: 6
Study 7261552 — intervention group
Group type: EXPERIMENTAL
Intervention: Metoprolol (100 mg b.i.d.)
Number of subjects: 6
Study 7261552 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 6
Study 29350459 — intervention group
Group type: EXPERIMENTAL
Intervention: NOURISH-T intervention
Number of subjects: 0
Study 29350459 — intervention group
Group type: COMPARATOR
Intervention: Enhanced Usual Care (EUC)
Number of subjects: 0
Study 26891648 — intervention group
Group type: EXPERIMENTAL
Intervention: Kinesiology tape (EG1, from origin to insertion)
Number of subjects: 30
Study 26891648 — intervention group
Group type: EXPERIMENTAL
Intervention: Kinesiology tape (EG2, from insertion to origin)
Number of subjects: 30
Study 26891648 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 30
Study 24820681 — intervention group
Group type: EXPERIMENTAL
Intervention: Static medial load for varus knees
Number of subjects: 15
Study 24820681 — intervention group
Group type: EXPERIMENTAL
Intervention: Static tibiofemoral alignment
Number of subjects: 15
Study 24820681 — intervention group
Group type: EXPERIMENTAL
Intervention: Dynamic medial load distributions
Number of subjects: 15
Study 24820681 — intervention group
Group type: EXPERIMENTAL
Intervention: Static plateau load distributions
Number of subjects: 15
Study 24820681 — intervention group
Group type: EXPERIMENTAL
Intervention: Dynamic medial load
Number of subjects: 15
Study 24820681 — intervention group
Group type: EXPERIMENTAL
Intervention: Tibiofemoral angle
Number of subjects: 15
Study 22828124 — intervention group
Group type: EXPERIMENTAL
Intervention: saxagliptin 2.5 mg q.A.M.
Number of subjects: 365
Study 22828124 — intervention group
Group type: EXPERIMENTAL
Intervention: saxagliptin 5 mg q.A.M.
Number of subjects: 365
Study 22828124 — intervention group
Group type: EXPERIMENTAL
Intervention: saxagliptin 5 mg q.P.M.
Number of subjects: 365
Study 22828124 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 365
Study 22828124 — intervention group
Group type: EXPERIMENTAL
Intervention: saxagliptin (all doses)
Number of subjects: 365
Study 22828124 — intervention group
Group type: COMPARATOR
Intervention: control (placebo)
Number of subjects: 365
Study 20980999 — intervention group
Group type: EXPERIMENTAL
Intervention: Pazopanib 800 mg with high-fat meal
Number of subjects: 0
Study 20980999 — intervention group
Group type: EXPERIMENTAL
Intervention: Pazopanib 800 mg with low-fat meal
Number of subjects: 0
Study 20980999 — intervention group
Group type: EXPERIMENTAL
Intervention: Pazopanib 400 mg with high-fat meal
Number of subjects: 0
Study 20980999 — intervention group
Group type: COMPARATOR
Intervention: Pazopanib in fasting condition
Number of subjects: 0
Study 18927270 — intervention group
Group type: EXPERIMENTAL
Intervention: Immobilization for 2 weeks
Number of subjects: 0
Study 18927270 — intervention group
Group type: EXPERIMENTAL
Intervention: Recovery for 2 weeks after immobilization
Number of subjects: 0
Study 18927270 — intervention group
Group type: EXPERIMENTAL
Intervention: Remobilization for 2 weeks
Number of subjects: 0
Study 18927270 — intervention group
Group type: EXPERIMENTAL
Intervention: Systemic concentrations of PINP
Number of subjects: 0
Study 18927270 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall findings
Number of subjects: 0
Study 15793044 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraoperative hemofiltration (HF)
Number of subjects: 80
Study 15793044 — intervention group
Group type: COMPARATOR
Intervention: Conventional treatment (CONV)
Number of subjects: 80
Study 11952027 — intervention group
Group type: EXPERIMENTAL
Intervention: Emedastine plus placebo capsules
Number of subjects: 80
Study 11952027 — intervention group
Group type: COMPARATOR
Intervention: Loratadine plus placebo eyedrops
Number of subjects: 80
Study 11952027 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of emedastine and loratadine
Number of subjects: 80
Study 10551714 — intervention group
Group type: EXPERIMENTAL
Intervention: Propionyl-L-carnitine (1 g bid, p.o.)
Number of subjects: 485
Study 10551714 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 485
Study 10551714 — intervention group
Group type: EXPERIMENTAL
Intervention: Propionyl-L-carnitine
Number of subjects: 485
Study 8635265 — intervention group
Group type: EXPERIMENTAL
Intervention: TAK-044 (10 to 1000 mg IV over a 15-minute period)
Number of subjects: 17
Study 8635265 — intervention group
Group type: EXPERIMENTAL
Intervention: TAK-044 (30, 250, and 750 mg IV)
Number of subjects: 17
Study 8635265 — intervention group
Group type: EXPERIMENTAL
Intervention: TAK-044 (1000 mg)
Number of subjects: 17
Study 8635265 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 17
Study 1947791 — intervention group
Group type: EXPERIMENTAL
Intervention: Cimetidine 400 mg three times daily for 6 days
Number of subjects: 339
Study 1947791 — intervention group
Group type: COMPARATOR
Intervention: Placebo three times daily for 6 days
Number of subjects: 339
Study 6339137 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgery
Number of subjects: 29
Study 6339137 — intervention group
Group type: COMPARATOR
Intervention: Chymopapain injection (4000 IU, 2 ml)
Number of subjects: 29
Study 30630860 — intervention group
Group type: EXPERIMENTAL
Intervention: Vorapaxar
Number of subjects: 0
Study 30630860 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 28763356 — intervention group
Group type: EXPERIMENTAL
Intervention: Multiport wire-reinforced flexible catheter
Number of subjects: 650
Study 28763356 — intervention group
Group type: COMPARATOR
Intervention: Uniport wire-reinforced flexible catheter
Number of subjects: 650
Study 28479899 — intervention group
Group type: EXPERIMENTAL
Intervention: nicardipine
Number of subjects: 340
Study 28479899 — intervention group
Group type: EXPERIMENTAL
Intervention: nicardipine+esmolol
Number of subjects: 340
Study 28479899 — intervention group
Group type: EXPERIMENTAL
Intervention: nitroglycerin
Number of subjects: 340
Study 28479899 — intervention group
Group type: EXPERIMENTAL
Intervention: nitroglycerin+esmolol
Number of subjects: 340
Study 28479899 — intervention group
Group type: COMPARATOR
Intervention: control (Group E)
Number of subjects: 340
Study 26460907 — intervention group
Group type: EXPERIMENTAL
Intervention: Individualized educational program
Number of subjects: 207
Study 26460907 — intervention group
Group type: COMPARATOR
Intervention: Conventional information
Number of subjects: 207
Study 22410480 — intervention group
Group type: EXPERIMENTAL
Intervention: Low frequency rTMS (1 Hz)
Number of subjects: 54
Study 22410480 — intervention group
Group type: EXPERIMENTAL
Intervention: Priming rTMS (6 Hz)
Number of subjects: 54
Study 22410480 — intervention group
Group type: COMPARATOR
Intervention: Sham rTMS
Number of subjects: 54
Study 21316537 — intervention group
Group type: EXPERIMENTAL
Intervention: Voriconazole (200 mg BID orally after a loading dose of 400 mg BID on day 1)
Number of subjects: 53
Study 21316537 — intervention group
Group type: COMPARATOR
Intervention: Itraconazole (100 mg BID orally, no loading dose)
Number of subjects: 53
Study 21316537 — intervention group
Group type: EXPERIMENTAL
Intervention: Voriconazole
Number of subjects: 53
Study 21316537 — intervention group
Group type: EXPERIMENTAL
Intervention: Voriconazole and Itraconazole
Number of subjects: 53
Study 18553458 — intervention group
Group type: EXPERIMENTAL
Intervention: R1626 500 mg
Number of subjects: 47
Study 18553458 — intervention group
Group type: EXPERIMENTAL
Intervention: R1626 1500 mg
Number of subjects: 47
Study 18553458 — intervention group
Group type: EXPERIMENTAL
Intervention: R1626 3000 mg
Number of subjects: 47
Study 18553458 — intervention group
Group type: EXPERIMENTAL
Intervention: R1626 4500 mg
Number of subjects: 47
Study 18553458 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 47
Study 16491958 — intervention group
Group type: EXPERIMENTAL
Intervention: SCDSF treatment
Number of subjects: 179
Study 16491958 — intervention group
Group type: COMPARATOR
Intervention: Conservative treatment
Number of subjects: 179
Study 12057718 — intervention group
Group type: EXPERIMENTAL
Intervention: Flutamide (250 mg twice daily)
Number of subjects: 22
Study 12057718 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 22
Study 10496247 — intervention group
Group type: EXPERIMENTAL
Intervention: Vigabatrin monotherapy
Number of subjects: 32
Study 10496247 — intervention group
Group type: COMPARATOR
Intervention: Carbamazepine monotherapy
Number of subjects: 32
Study 10496247 — intervention group
Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 32
Study 8756741 — intervention group
Group type: EXPERIMENTAL
Intervention: t‐PA
Number of subjects: 30
Study 8756741 — intervention group
Group type: EXPERIMENTAL
Intervention: PAI‐1
Number of subjects: 30
Study 8756741 — intervention group
Group type: EXPERIMENTAL
Intervention: alpha 2‐antiplasmin
Number of subjects: 30
Study 8756741 — intervention group
Group type: EXPERIMENTAL
Intervention: plasminogen activity
Number of subjects: 30
Study 8756741 — intervention group
Group type: EXPERIMENTAL
Intervention: fibrin degradation products (FDP)
Number of subjects: 30
Study 8756741 — intervention group
Group type: EXPERIMENTAL
Intervention: euglobulin lysis time (ELT)
Number of subjects: 30
Study 8756741 — intervention group
Group type: EXPERIMENTAL
Intervention: t‐PA and PAI‐1
Number of subjects: 30
Study 8756741 — intervention group
Group type: EXPERIMENTAL
Intervention: plasminogen and alpha 2‐AP
Number of subjects: 30
Study 8756741 — intervention group
Group type: EXPERIMENTAL
Intervention: FDP
Number of subjects: 30
Study 8756741 — intervention group
Group type: EXPERIMENTAL
Intervention: examined parameters
Number of subjects: 30
Study 1837202 — intervention group
Group type: EXPERIMENTAL
Intervention: McArdle's disease
Number of subjects: 19
Study 1837202 — intervention group
Group type: EXPERIMENTAL
Intervention: Acid maltase deficiency
Number of subjects: 19
Study 6360703 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhalation powder (1 mg fenoterol, 5 doses of 0.2 mg over 10 minutes)
Number of subjects: 15
Study 6360703 — intervention group
Group type: COMPARATOR
Intervention: Pressurized aerosol (1 mg fenoterol, 5 doses of 0.2 mg over 10 minutes)
Number of subjects: 15
Study 30449623 — intervention group
Group type: EXPERIMENTAL
Intervention: Cisplatin (100 mg/m2 on days 1, 22, and 43 of radiotherapy)
Number of subjects: 334
Study 30449623 — intervention group
Group type: COMPARATOR
Intervention: Cetuximab (400 mg/m2 loading dose followed by seven weekly infusions of 250 mg/m2)
Number of subjects: 334
Study 30449623 — intervention group
Group type: EXPERIMENTAL
Intervention: Cisplatin
Number of subjects: 334
Study 30449623 — intervention group
Group type: COMPARATOR
Intervention: Cetuximab
Number of subjects: 334
Study 29959763 — intervention group
Group type: EXPERIMENTAL
Intervention: Recombinant human growth hormone replacement therapy
Number of subjects: 57
Study 29959763 — intervention group
Group type: COMPARATOR
Intervention: No recombinant human growth hormone replacement therapy
Number of subjects: 57
Study 29959763 — intervention group
Group type: COMPARATOR
Intervention: Surgical treatment and cranial radiotherapy
Number of subjects: 57
Study 29959763 — intervention group
Group type: COMPARATOR
Intervention: Interferon‐α exclusively
Number of subjects: 57
Study 29959763 — intervention group
Group type: EXPERIMENTAL
Intervention: General treatment outcomes
Number of subjects: 57
Study 26861603 — intervention group
Group type: EXPERIMENTAL
Intervention: Letrozole 2.5 mg daily for 5 years
Number of subjects: 360
Study 26861603 — intervention group
Group type: COMPARATOR
Intervention: Observation
Number of subjects: 360
Study 26861603 — intervention group
Group type: EXPERIMENTAL
Intervention: Letrozole
Number of subjects: 360
Study 24402594 — intervention group
Group type: EXPERIMENTAL
Intervention: Mechanical bowel preparation (clear liquid diet and two self-administered saline enemas)
Number of subjects: 150
Study 24402594 — intervention group
Group type: COMPARATOR
Intervention: Regular diet and nothing by mouth after midnight (Control)
Number of subjects: 150
Study 24402594 — intervention group
Group type: EXPERIMENTAL
Intervention: Mechanical bowel preparation
Number of subjects: 150
Study 21922153 — intervention group
Group type: EXPERIMENTAL
Intervention: Gemcitabine plus Paclitaxel (GT)
Number of subjects: 351
Study 21922153 — intervention group
Group type: COMPARATOR
Intervention: Paclitaxel monotherapy (T)
Number of subjects: 351
Study 19116178 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-molecular-weight heparin plus low-dose aspirin
Number of subjects: 85
Study 19116178 — intervention group
Group type: COMPARATOR
Intervention: Intravenous immunoglobulin (IVIG)
Number of subjects: 85
Study 17439900 — intervention group
Group type: EXPERIMENTAL
Intervention: Glatiramer acetate (GA)
Number of subjects: 60
Study 17439900 — intervention group
Group type: EXPERIMENTAL
Intervention: Interferon-beta 1a (IFN-β 1a)
Number of subjects: 60
Study 17439900 — intervention group
Group type: EXPERIMENTAL
Intervention: Immunoglobulins (Igs)
Number of subjects: 60
Study 17439900 — intervention group
Group type: EXPERIMENTAL
Intervention: Interferon-beta 1a (IFN-β 1a) and Glatiramer acetate (GA)
Number of subjects: 60
Study 17660643 — intervention group
Group type: EXPERIMENTAL
Intervention: Fuji‐VII glass ionomer cement
Number of subjects: 0
Study 17660643 — intervention group
Group type: COMPARATOR
Intervention: Light-cured unfilled resin
Number of subjects: 0
Study 14751336 — intervention group
Group type: EXPERIMENTAL
Intervention: KNa-Cit and MgO (combined)
Number of subjects: 39
Study 14751336 — intervention group
Group type: COMPARATOR
Intervention: KNa-Cit (alone)
Number of subjects: 39
Study 14751336 — intervention group
Group type: COMPARATOR
Intervention: MgO (alone)
Number of subjects: 39
Study 11207003 — intervention group
Group type: EXPERIMENTAL
Intervention: Goserelin
Number of subjects: 149
Study 11207003 — intervention group
Group type: EXPERIMENTAL
Intervention: Tamoxifen
Number of subjects: 149
Study 11207003 — intervention group
Group type: EXPERIMENTAL
Intervention: Goserelin plus Tamoxifen
Number of subjects: 149
Study 11207003 — intervention group
Group type: COMPARATOR
Intervention: Control (systematically untreated)
Number of subjects: 149
Study 9075032 — intervention group
Group type: EXPERIMENTAL
Intervention: Zolpidem 10 mg
Number of subjects: 357
Study 9075032 — intervention group
Group type: EXPERIMENTAL
Intervention: Triazolam 0.25 mg
Number of subjects: 357
Study 9075032 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 357
Study 8214530 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol/alfentanil
Number of subjects: 40
Study 8214530 — intervention group
Group type: COMPARATOR
Intervention: Thiopentone/isoflurane/alfentanil
Number of subjects: 40
Study 3011257 — intervention group
Group type: EXPERIMENTAL
Intervention: Etoposide (VP-16) at 300 mg/m2
Number of subjects: 79
Study 3011257 — intervention group
Group type: EXPERIMENTAL
Intervention: Etoposide (VP-16) at 600 mg/m2
Number of subjects: 79
Study 3011257 — intervention group
Group type: EXPERIMENTAL
Intervention: Etoposide (VP-16) at 900 mg/m2
Number of subjects: 79
Study 31550381 — intervention group
Group type: EXPERIMENTAL
Intervention: Goal setting and attainment intervention
Number of subjects: 60
Study 31550381 — intervention group
Group type: EXPERIMENTAL
Intervention: Resource program contacts
Number of subjects: 60
Study 31550381 — intervention group
Group type: EXPERIMENTAL
Intervention: Goal track
Number of subjects: 60
Study 31550381 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 60
Study 28864675 — intervention group
Group type: EXPERIMENTAL
Intervention: G-tube placement
Number of subjects: 481
Study 25977146 — intervention group
Group type: EXPERIMENTAL
Intervention: Trimethoprim‐sulfamethoxazole 320 mg/1600 mg twice daily
Number of subjects: 252
Study 25977146 — intervention group
Group type: COMPARATOR
Intervention: Vancomycin 1 g twice daily
Number of subjects: 252
Study 25977146 — intervention group
Group type: EXPERIMENTAL
Intervention: Trimethoprim‐sulfamethoxazole
Number of subjects: 252
Study 25977146 — intervention group
Group type: COMPARATOR
Intervention: Vancomycin
Number of subjects: 252
Study 25977146 — intervention group
Group type: EXPERIMENTAL
Intervention: Both treatments
Number of subjects: 252
Study 23686085 — intervention group
Group type: EXPERIMENTAL
Intervention: Tourniquet group (T group)
Number of subjects: 51
Study 23686085 — intervention group
Group type: COMPARATOR
Intervention: No tourniquet group (NT group)
Number of subjects: 51
Study 21132308 — intervention group
Group type: EXPERIMENTAL
Intervention: Pitavastatin (2 mg/day)
Number of subjects: 24
Study 21132308 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study 19438487 — intervention group
Group type: EXPERIMENTAL
Intervention: Microwave endometrial ablation (MEA)
Number of subjects: 263
Study 19438487 — intervention group
Group type: COMPARATOR
Intervention: Transcervical resection of the endometrium (TCRE)
Number of subjects: 263
Study 16732143 — intervention group
Group type: EXPERIMENTAL
Intervention: One dose of dexamethasone
Number of subjects: 90